Janus Henderson Group
ELVN icon

Janus Henderson Group’s Enliven Therapeutics ELVN Stock Holding History

Janus Henderson Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$431K Sell
11,000
-1,660,724
-99% -$46M ﹤0.01% 2081
2025
Q4 		$25.7M Sell
1,671,724
-121,859
-7% -$2.43M 0.01% 553
2025
Q3 		$36.7M Buy
1,793,583
+77,171
+4% +$1.56M 0.02% 476
2025
Q2 		$34.4M Buy
1,716,412
+145,909
+9% +$2.76M 0.02% 463
2025
Q1 		$33.1M Buy
1,570,503
+238,626
+18% +$5.14M 0.02% 452
2024
Q4 		$30M Buy
1,331,877
+290,153
+28% +$7.52M 0.02% 504
2024
Q3 		$26.6M Buy
1,041,724
+313,019
+43% +$7.25M 0.01% 517
2024
Q2 		$17M Buy
728,705
+14,794
+2% +$311K 0.01% 598
2024
Q1 		$12.6M Buy
713,911
+305,397
+75% +$4.69M 0.01% 647
2023
Q4 		$5.68M Buy
408,514
+132,098
+48% +$1.62M ﹤0.01% 786
2023
Q3 		$3.77M Sell
276,416
-94,578
-25% -$1.59M ﹤0.01% 900
2023
Q2 		$7.57M Sell
370,994
-231,160
-38% -$4.67M ﹤0.01% 745
2023
Q1 		$13.2M Buy
602,154
+369,977
+159% +$7.53M 0.01% 658
2022
Q4 		$3.77M Buy
+232,177
New +$3.71M ﹤0.01% 925

Other funds holding ELVN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Janus Henderson Group's ELVN Position: Q1 2026 in Review

Janus Henderson Group reduced its Enliven Therapeutics (ELVN) stake by 99% in Q1 2026, selling an estimated $46M and leaving 11,000 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #2081.

Janus Henderson Group first reported a position in ELVN in Q4 2022 and has held it in 14 quarters since. The position peaked at $36.7M in Q3 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Janus Henderson Group held 11,000 shares of Enliven Therapeutics worth $431K as of Q1 2026.
  • Janus Henderson Group sold 1,660,724 Enliven Therapeutics shares in Q1 2026, an estimated $46M.
  • Enliven Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2081 holding.
  • Janus Henderson Group first reported a position in Enliven Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Janus Henderson Group's Enliven Therapeutics position peaked at $36.7M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.